NTRA - Medicare extends coverage of Natera's Signatera test to muscle invasive bladder cancer
- Natera ( NASDAQ: NTRA ) on Monday said Medicare coverage for its Signatera diagnostic test had been extended to patients with muscle invasive bladder cancer, effective April 19.
- The company said it had received written confirmation on the extension of coverage from the CMS Molecular Diagnostics Services Program, which was developed in 2011 to establish coverage and reimbursement for molecular diagnostic tests.
- NTRA's Signatera is a custom-built circulating tumor DNA test for the assessment, treatment and monitoring of molecular residual disease in patients previously diagnosed with cancer.
- Signatera already has existing Medicare coverage for use in patients with colorectal cancer and for pan-cancer immunotherapy monitoring.
- NTRA stock +3.5% to $47.41 in early trading.
For further details see:
Medicare extends coverage of Natera's Signatera test to muscle invasive bladder cancer